BIOA Stock Analysis: Buy, Sell, or Hold?
BIOA - BioAge Labs, Inc. Common Stock
$23.76
1.14 (5.04%)
β²
5d:
+14.4%
30d:
+40.18%
90d:
+46.22%
WAIT
LOW Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When BIOA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
βΈοΈ WAIT FOR BETTER ENTRY: BIOA is 15.0% above its trading range ($20.66). While momentum could continue, risk/reward favors waiting for a pullback.
βΈοΈ WAIT FOR BETTER ENTRY: BIOA is 15.0% above its trading range ($20.66). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: BIOA is currently trading at $23.76, which is considered extended relative to its 30-day fair value range of $15.52 to $20.66.
Technical Outlook: Technically, BIOA is in a downtrend. Immediate support is located at $16.07, while resistance sits at $24.93. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: BIOA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.50 (+108.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BIOA is in a downtrend. Immediate support is located at $16.07, while resistance sits at $24.93. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: BIOA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.50 (+108.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.52 -
$20.66
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+15.0% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.0%)
- BULLISH: Trading 108.3% below Wall St target ($49.50)
- WARNING: Recommendation downgraded due to 15.0% overvaluation
Trading Range Analysis
30-Day Trading Range
$15.52 -
$20.66
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.07
Resistance Level
$24.93
Current Trend
Downtrend
Technical data as of
Jun 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.53
Wall Street Target
$49.50
(+108.3%)
Revenue Growth (YoY)
91.0%
Share & Embed Analysis
Last updated: June 27, 2026 2:57 PM ET
Data refreshes hourly during market hours. Next update: 3:57 PM
Data refreshes hourly during market hours. Next update: 3:57 PM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIOA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Paul D Rubin
SELL
7433 shares
2026-02-02
Dov A Md Goldstein
SELL
27000 shares
2026-01-13
Kristen Fortney
SELL
233107 shares
2026-01-13
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I⦠|
STRONG BUY
25 analysts |
$194 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp⦠|
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals⦠|
STRONG BUY
12 analysts |
$21 | 54 HOLD |